Sponsors and Collaborators
Mackay Memorial Hospital
Principal Investigator: Hui-Ju Chen MD, Department of Pediatric Neurology, MacKay Children's Hospital
Autism Spectrum Disorders (ASD) comprises a complex group of disorders of neuronal development characterized by social and communication impairment along with presence of repetitive and restrictive behaviors. Emerging evidences support the gut-brain axis and further microbiota-gut-brain axis. Elevated prevalence of gastrointestinal (GI) dysfunction in individuals with ASD suggested that targeting gut may benefit patients with ASD. Lactobacillus plantarum PS128® (PS128®) was reported to be a psychobiotic in several animal studies which modulated the levels of neurotransmitters in different brain areas. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128® in preschool children with ASD.
The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128® in preschool children with ASD. Children age 30 Months to 7 Years with ASD will receive PS128® treatment or placebo for 8 weeks. Symptoms of ASD and gut microbiota will be evaluated before and after the treatment, and the results will be compared.